CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), John F. Seymour(The Royal Melbourne Hospital), Talha Munir(Leeds Teaching Hospitals NHS Trust), Constantine S. Tam(The Alfred Hospital), Kenneth Wu(Düsseldorf University Hospital), Paolo Ghia(Vita-Salute San Raffaele University), Motohisa Takai(Universidad San Carlos), Patrick Phuong, Mark‐David Levin(Albert Schweitzer Hospital), Shelonitda Rose(Universidad San Carlos), Sheel Patel(Universidad San Carlos)
Cited by 1
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k